Nobumichi Tanaka, Yasushi Nakai, Isao Asakawa, Kaori Yamaki, Makito Miyake, Shunta Hori, Takuya Owari, Tomomi Fujii, Kiyohide Fujimoto. Local dose (biologically effective dose ≥180 Gy2) is an important predictor of biochemical recurrence in patients undergoing low-dose-rate brachytherapy. International journal of urology : official journal of the Japanese Urological Association. 2022
Ryosuke Matsuda, Masatoshi Hasegawa, Tetsuro Tamamoto, Nobuyoshi Inooka, Mei Nikimoto, Tomoko Ochi, Toshiteru Miyasaka, Shigeto Hontsu, Kaori Yamaki, Sachiko Miura, et al. Long-Term Survival after Linac-Based Stereotactic Radiosurgery and Radiotherapy with a Micro-Multileaf Collimator for Brain Metastasis. Current oncology (Toronto, Ont.). 2022. 29. 9. 6068-6076
Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Yosuske Morizawa, Kaori Yamaki, Shunta Hori, Daisuke Gotoh, Makito Miyake, Kazumasa Torimoto, Masatoshi Hasegawa, et al. Late genitourinary and gastrointestinal toxicity and radiation-induced second primary cancers in patients treated with low-dose-rate brachytherapy. Brachytherapy. 2022. 21. 5. 626-634
Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Makito Miyake, Satoshi Anai, Kazumasa Torimoto, Kaori Yamaki, Tomomi Fujii, Masatoshi Hasegawa, Kiyohide Fujimoto. Mirabegron Reduces Urinary Frequency and Improves Overactive Bladder Symptoms at 3 Months After 125I-brachytherapy for Prostate Cancer: An Open-Labeled, Randomized, Non-Placebo-Controlled Study. Urology. 2022. 161. 87-92
Yasushi Nakai, Nobumichi Tanaka, Isao Asakawa, Makito Miyake, Satoshi Anai, Kaori Yamaki, Masatoshi Hasegawa, Kiyohide Fujimoto. Erectile dysfunction and sexual quality of life in patients who underwent low-dose-rate brachytherapy alone for prostate cancer. Andrologia. 2022. 54. 1. e14288
